FITC-Labeled Human CD30, His Tag (Cat. No. CD0-HF2H3) is expressed from human HEK293 cells. It contains AA Phe 19 - Lys 379 (Accession # NP_001234.2). It is the FITC labeled form of Human CD30, His Tag (Cat. No. CD0-H5229).
Predicted N-terminus: Phe 19
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 39.3 kDa. The protein migrates as 60-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular seive treatment during purification process.
The FITC to protein molar ratio is 2-3.5.
Less than 1.0 EU per μg by the LAL method.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
FITC-Labeled Human CD30, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Anti-CD30 Mab (Human IgG1) at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human CD30, His Tag (Cat. No. CD0-HF2H3) with a linear range of 0.04-1.25 μg/mL (QC tested).
Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.